Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug

Park, Chun Gwon; Kim, Young Kook; Kim, Mi Jeung; Park, Min; Kim, Myung Hun; Lee, Seung Ho; Choi, Seulggie; Lee, Won Seok; Chung, You Jung; Jung, Young Eun; Park, Ki Ho; Choy, Young Bin

doi:10.1016/j.jconrel.2015.10.027

Cited by 41 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultssupporting

confidence: 90%

“…The MS prepared by the conventional emulsion method exhibited a spherical shape and a smooth surface, whereas the NM showed a rough nanofibrous surface192021. The overall morphologies of the MS and NM were not influenced by the presence of PEG, RSV or DTTCI, in accordance with our previous study192021. Here, the MS and NM were prepared so that they possessed a similar size distribution, which was measured to be 6.72–7.64 μm (Figure S2 and Table S1 in the Supplementary Information).…”

Section: Resultsmentioning

confidence: 98%

“…In the present study, mucoadhesive nanostructured microparticles (PLGA/PEG NM) were fabricated based on the method reported in our previous study19, wherein a solution containing both PLGA and PEG was electrospun to produce a nanofibrous sheet that was then freeze-milled to yield microparticles with a nanostructured morphology. As controls, we also prepared three other distinct types of microparticles: spherical microparticles without mucoadhesion (i.e., spherical microparticles with PLGA only; PLGA MS), spherical microparticles with mucoadhesion (i.e., spherical microparticles with a blend of PLGA and PEG; PLGA/PEG MS) and nanostructured microparticles without mucoadhesion (i.e., nanostructured microparticles with PLGA only; PLGA NM).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Resveratrol (RSV) has been shown to effectively suppress chronic rhinosinusitis with nasal polyps in a mouse model; however, when locally administered to the sinonasal cavity, bolus RSV is limited by low drug bioavailability owing to its low aqueous solubility and relatively rapid clearance from the administration site. To address this limitation, we propose mucoadhesive nanostructured microparticles (PLGA/PEG NM) as a potential carrier for the sinonasal delivery of RSV. In this study, PLGA/PEG NM released RSV in a sustained manner. Owing to the enlarged specific surface area of the nanostructures, PLGA/PEG NM had synergistically enhanced mucoadhesiveness and thus showed improved in vivo retention properties in the sinonasal cavity. Therefore, when tested in a mouse nasal polyp model, PLGA/PEG NM mitigated polyp formation and restored epithelial integrity better than the control treatments. The therapeutic effect was similar at half the dose of PLGA/PEG NM, suggesting improved local bioavailability of RSV in the sinonasal cavity.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Resultsmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…23 The permeability of brimonidine tartrate in BT/mcDH and BT/PBS was evaluated. The receiver chamber was filled with PBS.…”

Section: Methodsmentioning

confidence: 99%

“…20–22 In addition, they do not cause blurriness. 23 Dendrimers constituted of a focal core and successive branching units, are well-defined branched macromolecules with highly compact three-dimensional nanostructures. The monomolecular dendrimer itself is a nanoparticle.…”

Section: Introductionmentioning

confidence: 99%

Mildly Cross-Linked Dendrimer Hydrogel Prepared via Aza-Michael Addition Reaction for Topical Brimonidine Delivery

Wang¹,

Williamson²,

Lancina³

2017

j biomed nanotechnol

View full text Add to dashboard Cite

In this work, we developed a mildly cross-linked dendrimer hydrogel (mcDH) via aza-Michael addition of polyamidoamine (PAMAM) dendrimer G5 and polyethylene glycol diacrylate (PEG-DA, Mn=575 g/mol). We chose the antiglaucoma drug brimonidine tartrate as a model drug and developed a new antiglaucoma drug formulation on the basis of mcDH. Cytotoxicity of the mcDH formulation to NIH3T3 fibroblasts, in vitro drug release kinetics and ex vivo drug permeability across the rabbit cornea were examined. We also studied interactions between PAMAM dendrimer and the drug using 1H NMR spectroscopy for a mechanistic understanding of brimonidine release from the mcDH. mcDH was found to be efficient unionizing brimonidine tartrate to form and encapsulate brimonidine free base for sustained release and enhanced corneal permeation.

show abstract

Material, Immunological, and Practical Perspectives on Eye Drop Formulation

Bennett

Chinnery

Downie

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Eye drops are the most common and inexpensive approach to topical ocular drug delivery. Eye drops offer a noninvasive treatment strategy; however, this can be detrimental to therapeutic efficacy when compared to invasive methods such as surgeries, implants, and injections. Improvements to the efficacy of the topical delivery of drugs to ocular tissues are currently being explored and much of this work centers on adjusting the formulation of the eye drops and prolonging the bioavailability of the therapeutic agent. This is often in preference to improving other patient‐focused or clinical factors. In this progress report, conventional, commercially available polymer eye drops are explored and the ability for current and future innovations to maintain the existing benefits of eye drops to the patient is assessed. The final materials and form of the drops (liquid, gel, or other) and the immunological implications for the user are explored. There is currently no consensus for how to most effectively improve the ocular retention and drug delivery capabilities of eye drops, but key issues are highlighted in the context of current methods under development, and potential questions and considerations for future innovations are raised.

show abstract

Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug

Cited by 41 publications

References 47 publications

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Mildly Cross-Linked Dendrimer Hydrogel Prepared via Aza-Michael Addition Reaction for Topical Brimonidine Delivery

Material, Immunological, and Practical Perspectives on Eye Drop Formulation

Contact Info

Product

Resources

About